<DOC>
	<DOCNO>NCT00003144</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell bad side effect chemotherapy . PURPOSE : Randomized phase I trial study effectiveness amifostine treat patient receive chemotherapy recurrent refractory solid tumor .</brief_summary>
	<brief_title>Chemotherapy Amifostine Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate ability amifostine facilitate increase dose escalation gemcitabine cisplatin . II . Compare dose limit toxicity gemcitabine cisplatin administer without amifostine patient . III . Determine maximum tolerate dose gemcitabine cisplatin administer amifostine patient . IV . Determine whether synergy produce administer gemcitabine cisplatin day . OUTLINE : This two stage study . The first stage randomize study , second stage dose escalation study . In first stage study , patient receive either intravenous gemcitabine/amifostine/cisplation ( GAP ) gemcitabine/cisplatin ( GP ) first cycle . Patients administer arm second cycle . In second stage study ( dose escalation ) , initial dose GP GAP give day 1 8 every 28 day . Dose escalation carry cohort 3 patient per dose level . If 1 3 patient experience dose limit toxicity ( DLT ) , 3 patient accrue dose level . The maximum tolerated dose ( MTD ) define low dose 2 6 2 3 patient experience DLT . Patients experience grade 3 4 toxicity tumor progression remove study . Patients reassess every 12 week . PROJECTED ACCRUAL : A total 32 patient accrue 12-24 month first stage study , 9-12 patient accrued second stage..</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory solid tumor Platinum sensitive PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 02 Life Expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL Other : No psychosis No significant medical illness No sensory neuropathy great grade 2 PRIOR CONCURRENT THERAPY : At least 3 week since prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>